Allurion Technologies, a company focused on combating obesity, presented two abstracts at Obesity Week 2024. The first abstract showcased real-world data from their largest cohort to date. Data collected from 19,428 patients across 72 countries between 2018 and 2023, utilizing the Allurion Program and tracked via the Allurion Virtual Care Suite, demonstrated an average total body weight loss of 12.2% at four months. This large-scale, real-world data reinforces the clinical significance of the Allurion Program’s weight loss results across a diverse population, complementing previously published data in over 26 peer-reviewed publications.
The second abstract focused on the Allurion Program’s effectiveness for individuals unresponsive to liraglutide, a GLP-1 medication. The study included 27 patients, of whom 55% experienced no weight loss and 45% lost less than 5% body weight while using GLP-1 medications. Remarkably, these same patients achieved an average weight loss of 17.6% after just four months with the Allurion Program. This finding is particularly significant given that a substantial portion of GLP-1 patients do not achieve significant weight loss, and it can take several months to determine treatment efficacy. The Allurion Program may offer a valuable alternative for this patient population.
Allurion’s weight loss platform features the Allurion Gastric Balloon, a swallowable, procedure-less intragastric balloon, coupled with the Allurion Virtual Care Suite. This suite includes the Allurion Mobile App for consumers, Allurion Insights with the Coach Iris AI Platform for healthcare providers, and the Allurion Connected Scale. The Virtual Care Suite is also available independently from the Allurion Program, enabling providers to personalize and manage weight loss therapies for patients, regardless of the specific treatment plan—whether it involves a gastric balloon, surgery, medication, or nutritional guidance. The Allurion Gastric Balloon is currently an investigational device in the United States.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
